Dr Reddy's split chairman and CEO roles between son and son-in-law in 2014

Dr Reddy's founder Kallam Anji Reddy died in March 2013, and his son-in-law G.V. Prasad was named chairman on top of his CEO job. A year later, in May 2014, the board reorganized: the founder's son K. Satish Reddy became chairman, while Prasad became co-chairman, managing director and CEO.

Business Standard called it a smooth succession 'ending speculation about the two competing for the top job.' Prasad had run the company for years and kept the executive role; Satish took corporate governance, government relations and CSR — a division the two men said they had reassessed for a year.

The decision was governance as a product: separate the chair from the CEO, keep both in the family, and let each man's strengths define his job. The company announced the new structure alongside its quarterly results, presenting it as permanent rather than a stopgap.

The split ended succession speculation: the founder's son chairs the board, the son-in-law runs the business as CEO, and it held for a decade.

Separating chairman and CEO removed the either-or choice between two heirs.

Satish kept the family's face; Prasad kept operational continuity.

Announcing with results made the governance change look deliberate, not rushed.

When two credible heirs exist, split the roles instead of picking a winner: chairman for governance and family stewardship, CEO for running the business — then let the arrangement outlive the founder.

The split held for years as Dr Reddy's navigated US FDA import alerts and generics price erosion, and the two men remained in their roles through the company's next growth phase — a rare Indian promoter-family succession that did not end in a public feud.